

# CITATION REPORT

List of articles citing

Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study

DOI: 10.1002/bmc.3127

Biomedical Chromatography, 2014, 28, 1112-7.

**Source:** <https://exaly.com/paper-pdf/59228770/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2015</b> , 981-982, 14-8	3.2	8
21	Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. <i>Archives of Pharmacal Research</i> , <b>2015</b> , 38, 2076-82	6.1	17
20	Determination and Pharmacokinetic Study of Pirfenidone in Rat Serum by High-Performance Thin-Layer Chromatography. <i>Journal of Chromatographic Science</i> , <b>2016</b> , 54, 1115-9	1.4	5
19	Determination of isavuconazole in rat plasma by UPLC-MS/MS: application to a pharmacokinetic study. <i>Analytical Methods</i> , <b>2016</b> , 8, 5025-5030	3.2	1
18	Development and validation of a liquid chromatography-tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 137, 90-95	3.5	5
17	Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 138, 197-205	3.5	22
16	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2017</b> , 1058, 102-107	3.2	8
15	Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 243-251	3.2	24
14	Quality by Design-Applied Liquid Chromatography-Tandem Mass Spectrometry Determination of Enzalutamide Anti-Prostate Cancer Therapy Drug in Spiked Plasma Samples. <i>Analytical Chemistry Insights</i> , <b>2017</b> , 12, 1177390117726776		3
13	Validation of an LC-MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 156, 170-180	3.5	11
12	Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer. <i>Biomedical Chromatography</i> , <b>2018</b> , 32, e4034	1.7	8
11	Development of a liquid chromatography-tandem mass spectrometry method for assaying cenobamate in rat plasma. <i>Journal of Liquid Chromatography and Related Technologies</i> , <b>2018</b> , 41, 992-997 <sup>1-3</sup>		3
10	Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , <b>2018</b> , 32, e4367	1.7	
9	Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry. <i>Scientific Reports</i> , <b>2019</b> , 9, 15008	4.9	10
8	Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2019</b> , 1106-1107, 26-34	3.2	15
7	Chromatographic Methods for Determination of Drugs Used in Prostate Cancer in Biological and Pharmacological Samples. <i>Critical Reviews in Analytical Chemistry</i> , <b>2019</b> , 49, 78-99	5.2	9
6	Practical Approach to Modeling the Impact of Amorphous Drug Nanoparticles on the Oral Absorption of Poorly Soluble Drugs. <i>Molecular Pharmaceutics</i> , <b>2020</b> , 17, 180-189	5.6	18

5	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6122-6131	12.9	4
4	Quality by design with design of experiments approach for development of a stability-indicating LC method for enzalutamide and its impurities in soft gel dosage formulation. <i>Biomedical Chromatography</i> , <b>2021</b> , 35, e5062	1.7	8
3	VALIDATED RP-HPLC METHOD FOR DETERMINATION OF ENZALUTAMIDE IN BULK DRUG AND PHARMACEUTICAL DOSAGE FORM. <i>Indian Drugs</i> , <b>2016</b> , 53, 46-50	0.2	5
2	Quantification of Newly Discovered Anti-Cancer Drug Enzalutamide in Bulk and Synthetic Mixture by Stability Indicating TLC Method. <i>Current Drug Discovery Technologies</i> , <b>2019</b> , 16, 104-112	1.5	1
1	Characteristics, properties, and analytical and bio-analytical methods of enzalutamide: A review. <b>2023</b> , 6,		0